News und Presse

Göttingen 20.09.2021

University of Göttingen and Archroma develop new method for treating wood

MBM Science Bridge GmbH successfully negotiated an agreement comprising the licensing of a novel technology for wood modification, which enables the transfer of this inventive technology from basic science into industry.

Wood scientists at the University of Göttingen, together with the Swiss company Archroma, a global specialty chemicals company, have developed a new method for turning affordable and ecologically friendly wood from European forests into high-quality, fire-resistant construction timber. Until now, European softwood and hardwood could either be structurally modified to have physical and biological properties similar to tropical hardwood, or it could be treated with chemicals to become fire resistant, where the chemicals would leach out of the wood by contact with water or weather. The structurally modified wood in most cases cannot be used in construction as a structural or cladding element due to strict fire safety regulations, and the hardwood is not suitable for outdoor use. This situation looks set to change thanks to this new method which will, in the future, be exclusively marketed worldwide by Archroma.



Göttingen, 7.5.2021

Entwicklung eines Blut-Absaugsystems zur Nutzung von Eigenblut bei Operationen

Links: durch klassisches, forciertes Absaugen teilweise zerstörte rote Blutkörperchen führen zu einer Rotfärbung des Blutplasmas. Rechts: deutlich reduzierte Blutschädigung durch Absaugen mit akustischer Rückkopplung, Quelle: Dr. Martin FriedrichBei dem Absaugen von Blut während einer Operation wird ein erheblicher Teil der Zellen im Blut geschädigt, daher ist es nicht erlaubt, abgesaugtes OP-Blut unaufbereitet in den menschlichen Körper zurückzuführen. Da Fremdbluttransfusionen immunologisch zunehmend kritisch gesehen werden, Blutspenden weltweit zurückgehen und dabei erhebliche Kosten generieren, bekommt die Retransfusion patienteneigenen Blutes zunehmend Bedeutung.

Mit einer neuen Erfindung aus der Universitätsmedizin Göttingen (UMG) kann die Qualität des abgesaugten Blutes deutlich verbessert werden. Die Patentverwertungsagentur MBM ScienceBridge hat einen Lizenzvertrag mit der ATMOS MedizinTechnik GmbH & Co. KG vermittelt, die die neue Technologie in ein blutschonendes Absaugsystem integrieren möchte.



Göttingen, 13.10.2020

Scientists at the University of Göttingen develop drug for antibody tumour therapy

Chemists at the University of Göttingen have developed new cytotoxic drugs which could revolutionise antibody-based tumour therapy approaches. The research team succeeded in modifying the natural product Duocarmycin into “prodrug” formats – which means that it only develops its effect once inside the tumour cell, thus reducing the likelihood of potential side effects on passage through the body. The University has entered into an exclusive licence agreement with the biotechnology company Iksuda Therapeutics for onward development and commercialisation in cancer therapeutics.

Antibody tumour therapies have enabled significant therapeutic benefits to patients suffering from cancer, autoimmune diseases and other serious diseases. However, many antibodies lack sufficient anti-tumour activity in the cell. This can be achieved by the use of antibody-drug conjugates (ADCs), where antibodies, which target specific cancer antigens, are armed with powerful cell-killing (cytotoxic) agents or ‘payloads’. ADCs have become powerful additions to the cancer treatment armoury, with several recent drug approvals and expanding clinical validation. However, most early-wave ADCs are associated with poor tolerability profiles, often due to a reduction in efficacy caused by the loss of the toxic payload whilst in circulation. Some programmes have failed as a result of low efficacy, where the payload is not active enough once inside the cell. ADC innovators, such as Iksuda, are working on the development of ADCs with a higher therapeutic index and finding safer ways to deliver potent cell-killing toxins. Iksuda has developed their own stable conjugation platform which reduces the risk of loss of efficacy.
One way to enhance both safety and efficacy of an ADC is to ensure that the payload is only released via tumour-activated mechanisms. With this approach, the precursors, called prodrugs, are able to release more potent payloads inside the cancer cell, with limited impact outside the cell.



Eine Tochter der